TheraCys® BCG
(Bacillus Calmette Guerin Vaccine)Phase 2Vaccine
This vaccine helps protect against tuberculosis by building immunity to the disease, and is given to people at high risk of developing TB. It can also be used to treat bladder cancer by being delivered directly into the bladder.[1] TheraCys® BCG is currently being investigated across 1 indication[3], with its most advanced program in Phase 2.[1]
TheraCys® BCG is one of 16 biologic programs targeting Non Muscle Invasive Bladder Cancer. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Non Muscle Invasive Bladder Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Bacillus Calmette-Guerin
AstraZenecaPhase 3
Disitamab Vedotin
PfizerPhase 2
Cretostimogene Grenadenorepvec
CCG Oncology, Inc.
Phase 3
Nadofaragene Firadenovec
FerringPhase 3
Trodelvy
GileadPreclinical
Gemcitabin
GGerman Cancer Research Center
Phase 2
TARA-002
PProtara Therapeutics
Phase 2
TheraCys® BCG
FFudan University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 2[1]
- Company
- FFudan University